2596MO Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.3212